These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1618887)

  • 21. Toxicity and immunologic effects of continuous infusion of recombinant human interleukin-2 administered by selective hepatic perfusion in dogs.
    Da Pozzo LF; Hough KL; Holder WD
    Surgery; 1992 Mar; 111(3):326-34. PubMed ID: 1542858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of elevated temperature on natural killer cell activity, lymphokine-activated killer cell activity and lectin-dependent cytotoxicity of human umbilical cord blood and adult blood cells.
    Shen RN; Lu L; Young P; Shidnia H; Hornback NB; Broxmeyer HE
    Int J Radiat Oncol Biol Phys; 1994 Jul; 29(4):821-6. PubMed ID: 8040029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolactin response of NK cells, but not of LAK cells, is deficient in patients with carcinoma of oral cavity and during aging.
    Chakraborty A; Chakraborty NG; Chattopadhyay U
    Int J Cancer; 1996 Mar; 66(1):65-9. PubMed ID: 8608969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo administration of low-dose human interleukin-2 induces lymphokine-activated killer cells for enhanced cytolysis in vitro.
    Hancock GE; Molloy A; Ab BK; Kiessling R; Becx-Bleumink M; Cohn ZA; Kaplan G
    Cell Immunol; 1991 Feb; 132(2):277-84. PubMed ID: 1988157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The induction of lymphokine-activated killer cells: increased cytotoxicity via long-term cultivation].
    Hartwig M; Körner IJ; Malz W
    Arch Geschwulstforsch; 1989; 59(2):73-7. PubMed ID: 2785787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Augmentation of cytotoxic activity by combination with interleukin 2 and interferon gamma].
    Tsunoda T; Tanimura H; Yamaue H; Tani M; Iwahashi M
    Nihon Gan Chiryo Gakkai Shi; 1990 Jun; 25(6):1110-8. PubMed ID: 2118938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of ASTA-Z 7575 (INN Maphosphamide) on human lymphokine-activated killer cell induction.
    Singh KP; Gupta RK; Shau H; Ray PK
    Immunopharmacol Immunotoxicol; 1993 Nov; 15(5):525-38. PubMed ID: 8301017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contribution of serum inhibitory factors and immune cellular defects to the depressed cell-mediated immunity in patients with head and neck cancer.
    Wanebo HJ; Blackinton D; Kouttab N; Mehta S
    Am J Surg; 1993 Oct; 166(4):389-94. PubMed ID: 8214299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The glycosylation profile of interleukin-2 activated human lymphocytes correlates to their anti-tumor activity.
    Voshol H; Dullens HF; Den Otter W; Vliegenthart JF
    Anticancer Res; 1996; 16(1):155-9. PubMed ID: 8615602
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Taurine attenuates recombinant interleukin-2-activated, lymphocyte-mediated endothelial cell injury.
    Finnegan NM; Redmond HP; Bouchier-Hayes DJ
    Cancer; 1998 Jan; 82(1):186-99. PubMed ID: 9428497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of recombinant human IL-2 in miniature swine.
    Nakajima K; Smith CV; Mixon A; Rosengard BR; Guzzetta PC; Spitzer TR; Eckhaus MA; Sachs DH
    Transplant Proc; 1991 Feb; 23(1 Pt 1):248-50. PubMed ID: 1990524
    [No Abstract]   [Full Text] [Related]  

  • 32. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
    Nio Y; Zighelboim J; Berek JS; Bonavida B
    Nat Immun Cell Growth Regul; 1990; 9(4):283-96. PubMed ID: 2215516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity.
    Watanabe H; Narumi K; Stewart CC; Arbuck SG; Foon KA; Goldrosen MH
    Anticancer Res; 1992; 12(6B):1925-33. PubMed ID: 1295440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro natural killer and lymphokine-activated killer activity in patients with bronchogenic carcinoma.
    Dunlap NE; Lane VG; Cloud GA; Tilden AB
    Cancer; 1990 Oct; 66(7):1499-504. PubMed ID: 1698527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells.
    Jewell AP; Worman CP; Giles FJ; Goldstone AH; Lydyard PM
    Leuk Lymphoma; 1992 Aug; 7(5-6):473-80. PubMed ID: 1362916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infection of K562 cells with influenza A virus increases their susceptibility to natural killer lysis.
    Eisenthal A; Marder O; Lifschitz-Mercer B; Skornick Y; Tirosh R; Irlin Y; Avtalion R; Deutsch M
    Pathobiology; 1997; 65(6):331-40. PubMed ID: 9491852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity inhibition of cytolytic lymphocytes by omeprazole.
    Scaringi L; Cornacchione P; Fettucciari K; Rosati E; Rossi R; Marconi P; Capodicasa E
    Scand J Immunol; 1996 Sep; 44(3):204-14. PubMed ID: 8795713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Augmentation of murine lymphokine (rIL-2)-activated killer cell activity by indomethacin.
    Chao TY; Ohnishi H; Chu TM
    Mol Biother; 1989; 1(6):318-22. PubMed ID: 2610950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of NK cell lymphokine responsiveness by pituitary-thyroid hormones during ontogeny in mice. Suggestion for a sequential neuroendocrine-immune cross-talk.
    Provinciali M; Di Stefano G; Fabris N
    Ann N Y Acad Sci; 1994 Nov; 741():73-80. PubMed ID: 7825828
    [No Abstract]   [Full Text] [Related]  

  • 40. Cytotoxicity of cytokine-induced killer cells coated with bispecific antibody against acute myeloid leukemia cells.
    Kaneko T; Fusauch Y; Kakui Y; Okumura K; Mizoguchi H; Oshimi K
    Leuk Lymphoma; 1994 Jul; 14(3-4):219-29. PubMed ID: 7950910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.